Metastatic Hormone-Sensitive Prostate Cancer: Benefits and Risks of Current and Emerging Treatment Options
| Overview / Abstract: |
Prostate cancer is the most common cancer in men in the U.S.; in 2018, more than 3 million men were living with the disease. For men in whom prostate cancer is local or regional, 5-year survival approaches 100%. For those with metastatic hormone-sensitive prostate cancer (mHSPC), however, the 5-year survival rate is only 30%. Androgen deprivation therapy (ADT) has long been a treatment mainstay for mHSPC but may be associated with cardiovascular (CV) risks. Recently, the ADT treatment paradigm for mHSPC was modified based on clinical trials demonstrating the effectiveness of docetaxel or abiraterone (with prednisone) in combination with ADT in improving survival in patients with mHSPC. Several other therapies combined with ADT are also available. In this Virtual Practice, you will meet with two prostate cancer patients—reviewing medical records, assessing symptoms, ordering tests, and evaluating the risks and benefits of different therapeutic options as you develop a treatment plan with the best chance of optimizing outcomes. Following each case presentation, you will have the opportunity to play Cranium Challenge, a rapid-fire categorization game that puts your clinical knowledge to the test. |
|
Expiration |
Aug 11, 2021 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Online |
|
Credits / Hours |
The University of Cincinnati designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. |
|
Accreditation |
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians. |
|
Presenters / Authors / Faculty |
Alicia K. Morgans, MD, MPH—Program Chair Tanya B. Dorff, MD Neal D. Shore, MD, FACS |
|
Activity Specialities / Related Topics |
Urology, Radiology / Imagery / Nuclear Medicine, Primary Care, Oncology / Cancer / Radiation Therapy, Internal Medicine, Geriatrics / LTC, Family Medicine, Cardiology / Cardiovascular |
|
Sponsors / Supporters / Grant Providers |
This activity is supported by independent educational grants from Astellas and Pfizer, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. |
|
Keywords / Search Terms |
Virtual, interactive, CME, Free, RedMedEd, Patient case, metastatic hormone sensitive prostate cancer; mHSPC; prostate cancer; androgen deprivation therapy; ADT; apalutamide; enzalutamide; abiraterone; androgen receptor-directed therapies; AR-directed therapies; ARDT; individualized treatment; cardiovascular disease; cardiovascular risk; GnRH agonist; GnRH antagonist; safety; risks and benefits |
|